Grail Inc. announced topline results from the randomized, controlled NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test in 142,000 participants aged 50–77 in England’s NHS over three years. The trial did not meet its primary endpoint of a statistically significant combined Stage III–IV reduction, but reported reductions in Stage IV diagnoses over sequential screening rounds (including greater than 20% reductions in rounds two and three) in a pre-specified group of 12 cancers, along with increased detection of Stage I–II cancers and a four-fold improvement in overall cancer detection rate versus standard screening alone. Detailed results have not yet been presented and are planned for submission for presentation at the ASCO 2026 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____LA91803) on February 19, 2026, and is solely responsible for the information contained therein.